A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders

Yoshiro Sawae, Yoshiyuki Niho, Takashi Okamura, Masahiro Murakawa, Takanori Teshima, Tomoaki Fujisaki, Kei Ikeda, Mitsuo Kozuru, Naokuni Uike, Makoto Katsuno, Hiroyuki Takahira, Michi Hashimoto, Sayuri Yamashita, Kousuke Obama, Junji Nishimura, Syusuke Hisano, Eiji Morioka, Morioki Ishibashi, Tomi Akiyoshi, Junji SuzumiyaHiroaki Nakajima, Toshiki Uchida, Tetsuya Yoshida, Fumitoshi Asahara, Kouko Sakai, Naohisa Takeichi, Hideki Ishikura, Atsushi Takita, Ryokichi Asayama, Tsunefumi Shibuya, Kazuo Yamasaki, Shuichi Taniguchi, Hisashi Gondoh, Shin Hayashi, Kouichi Akashi, Seiji Motomura, Toshiyuki Ishimaru, Yusei Yamamoto, Kimiaki Ikeda, Yujiroh Yamano, Hiromi Iwasaki, Masayuki Sano, Yoshiroh Ohta, Eijo Matsuishi, Shinichi Hiramatsu, Akihiro Masumoto, Hideaki Kishikawa, Shuichi Koarada

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Using the envelope method, we allocated 125 patients with infections accompanied by hematopoietic disorders into two groups treated with imipenem/cilastatin sodium (IPM/CS) at a daily dose of 1 g/1 g b.i.d. (group BID) or 0.5 g/0.5 g q.i.d. (group QID), and obtained the following results. 1. in group BID, ANLL was observed in 25 patients; ALL in 6; and NHL in 12. in group QID, ANLL was observed in 27 patients; ALL in 7; and NHL in 13. 2. in group BID, efficacy rates were 54.5% (6/11) in sepsis, 63.0% (17/27) in fever of undetermined origin and 50.0% (4/8) in pneumonia, thus the overall efficacy was 61.8% (34/55). in group QID, efficacy rates were 66.7% (4/6) in sepsis, 76.0% (19/25) in fever of undetermined origin and 35.7% (5/14) in pneumonia, thus the over all was 61.1% (33/54). No significant difference in response rates were observed between the two groups. 3. Bacteriologically, 22 bacterial strains were isolated in group BID and 21 strains, in group QID. the eradication rates after treatment with IPM/CS was 100% in group BID and 66.7% in group QID. 4. Side effects were observed in 8 patients in group BID and 3 in group QID. Laboratory examination revealed abnormal values in 9 patients in group BID and 6 in group QID. However, all of the side effects desappeared after the suspension or discontinuation of IPM/CS. the efficacies of IPM/CS therapy for severe infections in patients with hematopoietic disease were similar between 1 g/1 g b.i.d. and 0.5 g/0.5 g q.i.d. groups.

Original languageEnglish
Pages (from-to)1318-1328
Number of pages11
JournalThe Japanese Journal of Antibiotics
Volume47
Issue number10
DOIs
Publication statusPublished - 1994
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders'. Together they form a unique fingerprint.

Cite this